Metraipolis › archive › dc_dbf32c530fcb

Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience — Europe PMC PMID:41462859

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41462859
DOI
10.3390/biomedicines13122844
License (as archived)
solo-consultazione
Archived
2026-11-08T09:03:18.352Z
SHA-256 of the archived text
30d96db71e747cb8117b2636761e2bbce2bc8ffa2e9252ec944f60d4c543709b
Stable URL of this page
https://metraipolis.com/documento/dc_dbf32c530fcb

How to cite

Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience — Europe PMC PMID:41462859 — Europe PMC (en), https://europepmc.org/article/MED/41462859 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_dbf32c530fcb (Metraipolis archive dc_dbf32c530fcb, sha256 30d96db71e747cb8117b2636761e2bbce2bc8ffa2e9252ec944f60d4c543709b)
BibTeX
@misc{dcdbf32c530fcb,
  title = {Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience — Europe PMC PMID:41462859},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41462859},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_dbf32c530fcb; sha256 30d96db71e747cb8117b2636761e2bbce2bc8ffa2e9252ec944f60d4c543709b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41462859. Agents can read the archived copy with the MCP tool read_document.